BioSig Technologies to feature its PURE EP System at complex arrhythmias symposium EPLive 2020

BioSig Technologies, Inc (NASDAQ:BSGM) reported that its PURE EP technology will be featured in several live cases broadcast during EPLive 2020, the fifth international symposium on complex arrhythmias. The company said a total of 21 live and 13 recorded cases will broadcast from the Electrophysiology Center at St. David’s Medical Center in Austin, Texas, with expert commentary that will serve as the primary teaching tool. BioSig Technologies CEO Kenneth Londoner said in a statement:  “We are thrilled to be included in EPLive, a very unique physician education event, and we appreciate all the effort that went into making this important conference a reality amidst the global pandemic. We are grateful to Dr. Natale and his colleagues at TCAI for the outstanding support they continue to provide to our team and to the entire faculty of EPLive for their dedication to improving patient outcomes through the introduction of sophisticated educational tools and techniques for the benefit of the global physician audience.” READ: BioSig Technologies looking to unlock the future of bioelectronic medicine BioSig’s PURE EP System designed to improve signal fidelity and uncover the full range of electrocardiogram (ECG) and intracardiac signals, elevating the standard of care in electrophysiology through enhanced signal acquisition, digital signal processing, and analysis. PURE EP will be highlighted in several patient cases conducted live by Andrea Natale, executive medical director of TCAI, and EPLive course director, and Joseph Gallinghouse, MD,  as part of a two-day educational meeting for practicing clinical cardiac electrophysiologists, electrophysiology fellows, and general cardiologists at the Texas Cardiac Arrhythmia Institute from December 3 to December 4, 2020. The company noted that more than 350 patient cases have been completed with the PURE EP System to date by 25 electrophysiologists across several clinical sites. Texas Cardiac Arrhythmia Institute at St. David’s Medical Center was the first clinical installation site for the evaluation of BioSig’s PURE EP System.  BioSig Technologies expects its advanced signal processing solutions will unlock the future of bioelectronic medicine, a rapidly-growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases.  Contact Sean at sean@proactiveinvestors.com